Fig. 1: Invasive disease-free survival in patients with microinvasive, lymph node-negative, HER2-positive breast cancer: stratification by number of microinvasive foci (1–4 vs. ≥5) and by receipt of adjuvant chemotherapy and/or HER2-targeted therapy (CT and/or H2TT) among patients with ≥5 foci of microinvasion. | npj Breast Cancer

Fig. 1: Invasive disease-free survival in patients with microinvasive, lymph node-negative, HER2-positive breast cancer: stratification by number of microinvasive foci (1–4 vs. ≥5) and by receipt of adjuvant chemotherapy and/or HER2-targeted therapy (CT and/or H2TT) among patients with ≥5 foci of microinvasion.

From: Treatment patterns and clinical outcomes of patients with HER2-positive T1micN0 breast cancer: a single-center analysis

Fig. 1

Comparison of iDFS between (a) patients with 1–4 vs. ≥5 microinvasive foci; (b) patients with ≥5 foci who received (yes) vs. did not receive (no) adjuvant CT and/or H2TT.

Back to article page